What is Evommune 's recognized expenses of warrants?

Evommune (EVMN) reported recognized expenses of warrants of $150 in Q4 2025.

What does recognized expenses of warrants mean?

The cumulative or periodic expense recognized in the income statement related to the issuance or valuation changes of warrants. This reflects the non-cash cost of equity-based financing arrangements on the company's profitability.

Evommune EVMN Recognized Expenses Of Warrants

Recognized Expenses Of Warrants at other companies

NovaGold ResourcesNG

$0-100%

NextNavNN

$3.24M—

SHA

SharonAI Holdings, Inc. Class A Common StockSHAZ

$111.25K—

Target HospitalityTH

$376K—

PrecigenPGEN

$0-100%

NewAmsterdam Pharma CompanyNAMS

-$5.94M+56.8%

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:RecognizedExpensesOfWarrants.

The official record: Evommune ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's recognized expenses of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's recognized expenses of warrants?: Evommune (EVMN) reported recognized expenses of warrants of $150 in Q4 2025.
What does recognized expenses of warrants mean?: The cumulative or periodic expense recognized in the income statement related to the issuance or valuation changes of warrants. This reflects the non-cash cost of equity-based financing arrangements on the company's profitability.